Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Karuna Therapeutics cut by analysts following news of Bristol-Myers Squibb acquisition
December 26, 2023 11:14 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) was downgraded by analysts at Leerink Partners, H.C. Wainwright and Maxim Group on Tuesday following news that the company will be acquired by Bristol-Myers Squibb (NYSE: BMY)for a total value of... More
Bristol-Myers Squibb (BMY) to buy RayzeBio (RYZB) for $4.1 billion
December 26, 2023 7:56 AM ESTPharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) announced Tuesday that it is acquiring RayzeBio (NASDAQ: RYZB) for $4.1 billion, strengthening its oncology portfolio with promising radiopharmaceutical therapeutics (RPTs).
The deal, valued at $62.50 per RayzeBio share, was... More
RayzeBio (RYZB) to Resume Trading at 7:30 a.m.
December 26, 2023 7:05 AM ESTRayzeBio (NASDAQ: RYZB) to Resume Trading at 7:30 a.m.
Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb... More